Outlook Therapeutics Inc News - OTLKW

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™...

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Live video webcast on Tuesday, June 18th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE...

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European...

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal...

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

OTLKW News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the Retina World Congress 2024

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

OTLKW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW) News

Outlook Therapeutics Inc (OTLKW)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

OTLKW News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

Outlook Therapeutics® to Present at the Retina World Congress 2024

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

OTLKW Discussion

Your Recent History